So earnings in mid November followed by possible cancer data in mid December combined with a little mutual fund window dressing could make for an early Christmas.
Whats DNDN's PE? 36 doesn't look so bad in comparison. Now look at rapidly growing earning estimates and recalculate MDVN's. Thats what people who make money in this market do.
If you have such distrust of the board you have no business owning shares.
Predicting sales that far out is a #$%$ shoot. I have to believe there will be new drugs in this space by than. Also MDVN gets a much smaller piece of the foreign sales as opposed to half of US. Absent a buyout I think its currently priced fairly, at least until they show some new sales growth. The wild card in my estimation is breast cancer results. It will be fun to watch all of this unfold. Understand I am coming at this from a different viewpoint with my original shares costing around $8 and I picked up a few more this spring in the 50's and 60's when bios took a hit. I used yesterday and today to lighten up and re balance a bit.
Considering that a week ago you said you were shorting this "fat pig" and claimed it would never go over 100 I don't believe much of what you say. Good luck with your DNDN though.
MDVN sales are rising rapidly and will son be cannibalizing the competitors (DNDN and JNJ) market share with its expanded approval.If your using its market cap to value DNDN your in for an expensive lesson. Your right that you won't be selling your shares, they have a high likelihood of becoming worthless.Unless a big company that wants the technology doesn't want to wait for a post bankruptcy buyout your on very thin ice.
Unless there is a bidding war I think $2 would be the maxi buyout price. This company is between the proverbial rock and a hard place. As for those pie in the sky amounts I would challenge anyone to show me the last time a company got bought for 20 or 30 times its recent share price. Its not reality but than neither are most of the conspiracy based posts here.
There are always a number of candidates being tested. Some pan out any many don't. I am not aware of any nearing approval or better acting drugs in the foreseeable future. For the sake of all men I hope new and better treatments are discovered.
I'm much better at math. MDVN up 1100% while DNDN sunk 97%. And yes I have been here since 2012 to take advantage of the rise. My curiosity as to why DNDN has such blind and faithful followers brings me to your board. Hope I didn't dangle any pronouns. Of course math people typically make more money than english majors.
Black and white huh. So Vanguard doesn't own any? So the Biotech ETF's don't own any? As for disclaimers, you ever listen to an ad for any drug? They all have disclaimers. Very few companies however suggest their shareholders may soon be holding worthless paper.
By than Xtandi will be well entrenched and I suspect bought out. Unlike the untruthful claims of a generic being available now its at least two years away. I will be long gone by than. Hopefully there will be new more effective products on the way also, Thats the way the game goes.
The people pumping DNDN do not have a very good track record. Place your bets where you wish and we will see who comes out ahead. Fantasy postings of $40 a share buyouts when your trading under $2 with threats of bankruptcy at your door? Good luck.
"101% owned by hedge fund insiders", wrong. Institutional ownership is high but they are not all hedge funds. As long as you DNDN followers continue to ignore reality and try and bend any news in your favor you will have a hard time making money. Spending more time interpreting your 10Q than worrying about MDVN holders would be a good start.
No, whats strange is that you are worried about last years sales. The market looks forward and earnings forecast for MDVN are being revised upward on a weekly basis. Some are suggesting 2 billion in sales in a year.
MDVN's fortunes are riding on Xtandi. Astellas has a broad stable of products which include half of Xtandi. As a result Astellas will be less volatile with most likely less upside potential. Widows and Orphans would do well with Astellas. I believe Bearofbleecker bought some Astellas a while back and can weigh in here.
Most people don't like helping those who come across as rude. I know the answer but would have tailored it to your specific reason for wanting to know. Given your reply you can learn on your own.